BillionToOne, Inc.
NASDAQ:BLLNMedical - Diagnostics & Research
+$0.84 today
- Market cap
- $4.37B
- Beta
- 0.90
- P/E (TTM)
- 182.6
- EPS (TTM)
- $0.55
Volume 1.44M
Average 0.59M
BLLN Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
BillionToOne, Inc.NASDAQ: BLLN
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses growth accelerates
Q2 FY2026 other income / expenses of $2.02M rose 44.4% year over year, ahead of the -144.3% change in trailing-twelve-month other income / expenses. Sequentially, it rose 198.5% from the prior quarter.
Context
- Other income / expenses amounted to 2.7% of revenue in FY2025, down 1.0 pp from a year earlier.
- Other income / expenses increased in 1 of the last 2 fiscal years.
What to watch
Whether quarterly growth of +44.4% holds above the trailing-twelve-month pace of -144.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (8.26M) USD
- Year-over-year change
- -247.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.26M) | -247.4% |
| FY2024 | 2024-12-31 | 5.61M | +142.5% |
| FY2023 | 2023-12-31 | (13.18M) | — |
Other Income / Expenses vs competitors
How BLLN compares with its peers on the latest reported figures
- BLLN's LTM Jun 2026 other income / expenses of -$5.4M is the 7th highest of the 9 companies compared; the peer median is $15.68M.
- Its year-over-year change of -144.3% is the 7th highest of 9, against a peer median of -12.8%.
- Other income / expenses amounts to 1.4% of revenue for BLLN, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $36.97M | -8.1% | — | 1.4% | |
| LTM Jun 2026 | $29.78M | -13.0% | — | 18.0% | |
| LTM Mar 2026 | $23.01M | +2.7% | +56.5% | 7.2% | |
| LTM Sep 2026 | $18.14M | -59.5% | — | 1.4% | |
| LTM Jun 2026 | $13.22M | -12.7% | — | 2.4% | |
| LTM Jun 2026 | $11.62M | +21.0% | — | 1.5% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | -$5.4M | -144.3% | — | 1.4% |
| LTM Mar 2026 | -$16.3M | -579.2% | — | 2.0% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$45.69M | -1071.7% | — | 10.1% |
| Peer median (excluding BLLN) | $15.68M | -12.8% | +56.5% | 2.2% | |
Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 71.73M | 152.58M | 305.11M |
| Cost of Revenue | 54.42M | 71.67M | 96.65M |
| Gross Profit | 17.31M | 80.92M | 208.46M |
| Gross Margin | 24.1% | 53.0% | 68.3% |
| Research & Development | 22.41M | 36.6M | 49.38M |
| Selling, General & Admin | 64.39M | 91.47M | 143.05M |
| Operating Expenses | 86.8M | 128.06M | 192.44M |
| Depreciation & Amortization | 6.46M | 11.69M | 11.91M |
| EBITDA | (72.94M) | (27.47M) | 19.76M |
| EBITDA Margin | -101.7% | -18.0% | 6.5% |
| Operating Income | (69.5M) | (47.15M) | 16.02M |
| Operating Margin | -96.9% | -30.9% | 5.3% |
| Interest Income | 3.46M | 5.82M | 7.75M |
| Interest Expense | 3.27M | 2.39M | 95K |
| Other Income / Expenses | (13.18M) | 5.61M | (8.26M) |
| Income Before Tax | (82.67M) | (41.54M) | 7.76M |
| Pre-Tax Margin | -115.3% | -27.2% | 2.5% |
| Income Tax Expense | 9K | 29K | 305K |
| Net Income | (82.68M) | (41.57M) | 7.45M |
| Net Margin | -115.3% | -27.2% | 2.4% |
| EPS (Basic) | (1.85) | (0.93) | 0.06 |
| EPS (Diluted) | (1.85) | (0.93) | 0.06 |
| Weighted Avg Shares | 44.72M | 44.72M | 45.8M |
| Weighted Avg Shares (Diluted) | 44.72M | 44.72M | 45.8M |
BillionToOne, Inc.
NASDAQ:BLLN
Intrinsic Alpha fair value
Locked
Current Price
$91.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.